Skip to main content

Remarkable Science
Changes Everything

Remarkable Science
Changes Everything

Remarkable Science
Changes Everything

Remarkable Science
Changes Everything

Remarkable Science
Changes Everything

Remarkable Science
Changes Everything

Remarkable Science
Changes Everything

Aesthetics Pipeline

Revance will initially address two of the largest demands within the facial aesthetics category.

View Product Pipeline >>

Therapeutics Pipeline

Therapeutic indications for botulinum toxin represent more than half of the global neurotoxin market.

View Product Pipeline >>

Stock Quote

16.90  -1.20 (-6.63%)

NASDAQ: RVNC - May 4, 4:00PM EDT

Learn More >>

DaxibotulinumtoxinA Topical Gel (RT001)

With investigational product candidate RT001 Topical, TransMTS® enables delivery of daxibotulinumtoxinA to the target tissue while eliminating the need for — and fear of — multiple injections.
 

Learn More >>

DaxibotulinumtoxinA for Injection (RT002)

With investigational product candidate RT002 Injectable, TransMTS® delivery may localize daxibotulinumtoxinA to the site of injection, which may result in an extended duration of response without unwanted spread to neighboring tissue.

Learn More >>

RT001 Topical and RT002 Injectable are investigational product candidates. Each is currently undergoing clinical studies for both therapeutic and aesthetic indications.